According to current guidelines, insulin remains the mainstay of treatment for in-hospital DM and the use of only a sliding scale insulin regimen is considered inappropriate in the hospital setting once it might be associated with poor glycemic control and thereafter higher infection rates, increased mortality and prolonged hospital stay. This evidence concerns the gene INS and infection.